Log in

Relevant bibliographies by topics / A Drugs / Journal articles

To see the other types of publications on this topic, follow the link: A Drugs.

Journal articles on the topic 'A Drugs'

Author: Grafiati

Published: 4 June 2021

Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'A Drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Khanapure, Amol, Pem Chuki, and Avinash De Sousa. "Drug Repositioning : Old Drugs For New Indications." Indian Journal of Applied Research 4, no. 8 (October 1, 2011): 462–66. http://dx.doi.org/10.15373/2249555x/august2014/119.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Bocharova, Inna Anatolevna, Vadim Agadzhanov, and Vadim Sagalaev. "Drug addiction. Drugs and their effects on man." Vestnik Volgogradskogo Gosudarstvennogo Universiteta. Serija 11. Estestvennye nauki, no. 2 (December 1, 2013): 22–27. http://dx.doi.org/10.15688/jvolsu11.2013.2.3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Isnenia, Isnenia. "Penggunaan Non-Steroid Antiinflamatory Drug dan Potensi Interaksi Obatnya Pada Pasien Muskuloskeletal." Pharmaceutical Journal of Indonesia 6, no. 1 (December 1, 2020): 47–55. http://dx.doi.org/10.21776/ub.pji.2020.006.01.8.

Full text

Abstract:

The main therapy on musculoskeletal patients is the use of non-steroidal anti-inflammatory drugs (NSAIDs) either as monotherapy or in combination with drugs of the same class or pain relievers from other groups. The use of more than one drugs have potentially caused drug-drug interactions that can affect to patient. This study was aimed to describe the patient's sociodemographic (sex, ages) and clinical (numbers of drugs, type of drugs and diagnose) characteristics, as well as to find the correlation between potential drug interactions with these variables. This research was a quantitative study with a cross sectional design. Data were taken from 100 medical records of patients who had diagnosed with top five musculoskeletal diseases. Data were analyzed descriptively for sex, ages, number of drugs, type of drugs, and potential drug interactions. Bivariate correlation with chi-square were conducted to find statistically significancy potential drug interactions with each variable consist of sex, ages, type of drugs and it’s diagnose. The result shows that the musculoskeletal patients were 44% male, 56% female. Most musculoskeletal patients were aged 18-65 years (78%). Patients who received drugs <5 were 68% and ≥ 5 were 32%. 54% of patients were taking the diclofenac and only 5% of patients were taking the two NSAIDs combination, diclofenac and ibuprofen. There was no significant correlation (p > 0,05) between potential drug interactions with age, sex, type of NSAID, and type of musculosceletal diseases.

APA, Harvard, Vancouver, ISO, and other styles

4

Renner, Rebecca. "Drams of Drugs and Dregs." Scientific American 286, no. 5 (May 2002): 29. http://dx.doi.org/10.1038/scientificamerican0502-29.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

D, Subba Reddy, Prasanthi G, Amruth Raj S, Hari Krishna T, Sowjanya K, and Shantha Kumari K. "EVALUATION OF ANTICANCER GENERIC DRUGS AND BRANDED DRUGS." Indian Research Journal of Pharmacy and Science 5, no. 1 (March 2018): 1378–91. http://dx.doi.org/10.21276/irjps.2018.5.1.16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Singh, Uday, Gurjeet Singh, and Randhir Singh. "A STUDY ON DRUG UTILIZATION PATTERN OF ANTIHYPERTENSIVE DRUGS IN TERTIARY CARE HOSPITAL." INDIAN RESEARCH JOURNAL OF PHARMACY AND SCIENCE 7, no. 2 (June 2020): 2184–93. http://dx.doi.org/10.21276/irjps.2020.7.2.11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Chawra, Himmat Singh, Y. S. Tanwar, Ritu M. Gilhotra, and S. K. Singh. "Gastroretentive drug delivery systems a potential approach for antihypertensive drugs: An updated review." Asian Pacific Journal of Health Sciences 5, no. 2 (June 2018): 217–23. http://dx.doi.org/10.21276/apjhs.2018.5.2.40.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Gillam, Tony. "Drugs or no drugs?" Nursing Standard 20, no. 23 (February 15, 2006): 26–27. http://dx.doi.org/10.7748/ns.20.23.26.s30.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Gao, Shan, Anoliefo Ijeoma Janefrancis, Qingwei Cui, Yuqian Mi, Zhou Tong, and Bingxue Yan. "RNAi drugs: Next generation drugs?" Chinese Science Bulletin 65, no. 7 (March 1, 2020): 540–46. http://dx.doi.org/10.1360/tb-2019-0211.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Andersen, T. "Are newer drugs better drugs?" Obesity Reviews 4, no. 2 (May 2003): 75. http://dx.doi.org/10.1046/j.1467-789x.2003.00097.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Bateman, D. N., and S. Chaplin. "New Drugs: Centrally acting drugs." BMJ 296, no. 6619 (February 6, 1988): 417–19. http://dx.doi.org/10.1136/bmj.296.6619.417.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Frey, Bruno S. "Drugs: Drugs, economics and policy." Economic Policy 12, no. 25 (October 1997): 387–98. http://dx.doi.org/10.1111/1468-0327.00026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Frey, Bruno S. "Drugs: Drugs, economics and policy." Economic Policy 12, no. 25 (October 1997): 387–98. http://dx.doi.org/10.1111/1468-0327.t01-1-00025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Kaniwa, Masa-aki. "Drugs, Quasi-drugs and Cosmetics :." Material Cycles and Waste Management Research 25, no. 3 (May 31, 2014): 173–79. http://dx.doi.org/10.3985/mcwmr.25.173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

PALA, Elif, and Tuba DENKÇEKEN. "Integrating sub-pathway analysis to identify candidate drugs for COVID-19." International Journal of Medical Reviews and Case Reports 4, Reports in Neurology, Neurosur (2020): 71. http://dx.doi.org/10.5455/ijmrcr.covid-19-drugs.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Suresh, Suresh, Pratiti Pratiti, Sunita Sunita, Sona Sona, Soni Soni, Tulika Tulika, and Mahalingam Mahalingam. "Over The Counter Drugs." Asian Pacific Journal of Health Sciences 1, no. 4 (October 2014): 365–69. http://dx.doi.org/10.21276/apjhs.2014.1.4.10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Jones, Jacquie. "Drugs." Callaloo 13, no. 2 (1990): 299. http://dx.doi.org/10.2307/2931703.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "DRUGS." Nursing 24, no. 12 (December 1994): 49–56. http://dx.doi.org/10.1097/00152193-199412000-00019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Izenman, Alan Julian. "Drugs." Statistical Science 16, no. 1 (February 2001): 35–57. http://dx.doi.org/10.1214/ss/998929475.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Forrest, Jill. "Drugs . . ." Medical Journal of Australia 159, no. 5 (September 1993): 352. http://dx.doi.org/10.5694/j.1326-5377.1993.tb137879.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Rushforth, Bruno. "Drugs." BMJ 328, Suppl S3 (March 1, 2004): 0403129. http://dx.doi.org/10.1136/sbmj.0403129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Spillane, Joseph F. "Drugs." JAMA 289, no. 15 (April 16, 2003): 1997. http://dx.doi.org/10.1001/jama.289.15.1997-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Cerami, A., and K. S. Warren. "Drugs." Parasitology Today 10, no. 10 (January 1994): 404–6. http://dx.doi.org/10.1016/0169-4758(94)90234-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Jovicic, Jelena, Branka Gvozdic, Ljubisa Volas, Tatjana Brkic, Natasa Petrovic, and Nebojsa Ladjevic. "Old drugs are new again (drugs)." Serbian Journal of Anesthesia and Intensive Therapy 39, no. 5-6 (2017): 159–66. http://dx.doi.org/10.5937/sjait1706159j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

O'connor, Louise, David Best, Rachel Best, and Jenny Rowley. "Missed Opportunities: Drugs and Drugs Education." Early Child Development and Care 141, no. 1 (January 1998): 73–109. http://dx.doi.org/10.1080/0300443981410106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Chang, Sang G., and Puzant C. Torigian. "Expired Drugs are not Dead Drugs." American Journal of Health-System Pharmacy 50, no. 3 (March 1, 1993): 447–48. http://dx.doi.org/10.1093/ajhp/50.3.447.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Zhao, Hong-Ping, Hong-Min Jiang, and Bing-Ren Xiang. "Discontinued drugs in 2011: cardiovascular drugs." Expert Opinion on Investigational Drugs 21, no. 10 (July 25, 2012): 1449–62. http://dx.doi.org/10.1517/13543784.2012.710198.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Williams, Robert. "Discontinued drugs in 2011: oncology drugs." Expert Opinion on Investigational Drugs 22, no. 1 (November 6, 2012): 9–34. http://dx.doi.org/10.1517/13543784.2013.739605.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Zhao, Hong-Ping, Hong-Min Jiang, and Bing-Ren Xiang. "Discontinued drugs in 2012: cardiovascular drugs." Expert Opinion on Investigational Drugs 22, no. 11 (August 30, 2013): 1437–51. http://dx.doi.org/10.1517/13543784.2013.832198.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Williams, Robert. "Discontinued drugs in 2012: oncology drugs." Expert Opinion on Investigational Drugs 22, no. 12 (October 8, 2013): 1627–44. http://dx.doi.org/10.1517/13543784.2013.847088.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Williams, Robert. "Discontinued drugs in 2007: oncology drugs." Expert Opinion on Investigational Drugs 17, no. 12 (November 3, 2008): 1791–816. http://dx.doi.org/10.1517/13543780802465737.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Xu-song, Zhang, and Xiang Bing-ren. "Discontinued drugs in 2007: cardiovascular drugs." Expert Opinion on Investigational Drugs 17, no. 12 (November 3, 2008): 1817–28. http://dx.doi.org/10.1517/13543780802465992.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Xu-song, Zhang, and Xiang Bing-ren. "Discontinued drugs in 2008: cardiovascular drugs." Expert Opinion on Investigational Drugs 18, no. 7 (June 24, 2009): 875–85. http://dx.doi.org/10.1517/13543780903020308.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Williams, Robert. "Discontinued drugs in 2008: oncology drugs." Expert Opinion on Investigational Drugs 18, no. 11 (August 11, 2009): 1581–94. http://dx.doi.org/10.1517/13543780903151806.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Suckling, Keith. "Discontinued drugs in 2005: cardiovascular drugs." Expert Opinion on Investigational Drugs 15, no. 11 (October 16, 2006): 1299–308. http://dx.doi.org/10.1517/13543784.15.11.1299.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Kelland, Lloyd. "Discontinued drugs in 2005: oncology drugs." Expert Opinion on Investigational Drugs 15, no. 11 (October 16, 2006): 1309–18. http://dx.doi.org/10.1517/13543784.15.11.1309.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Kerwin, Robert. "Discontinued drugs in 2005: schizophrenia drugs." Expert Opinion on Investigational Drugs 15, no. 12 (November 15, 2006): 1487–95. http://dx.doi.org/10.1517/13543784.15.12.1487.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Williams, Robert. "Discontinued drugs in 2006: oncology drugs." Expert Opinion on Investigational Drugs 17, no. 3 (March 2008): 269–83. http://dx.doi.org/10.1517/13543784.17.3.269.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Zhao, Hong-ping, Xu-song Zhang, and Bing-ren Xiang. "Discontinued drugs in 2010: cardiovascular drugs." Expert Opinion on Investigational Drugs 20, no. 10 (August 26, 2011): 1311–25. http://dx.doi.org/10.1517/13543784.2011.611500.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Williams, Robert. "Discontinued drugs in 2010: oncology drugs." Expert Opinion on Investigational Drugs 20, no. 11 (September 28, 2011): 1479–96. http://dx.doi.org/10.1517/13543784.2011.623697.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Prinz, Aloys. "Drugs: Do European drugs policies matter?" Economic Policy 12, no. 25 (October 1997): 371–85. http://dx.doi.org/10.1111/1468-0327.00025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Zaccara, Gaetano, and Emilio Perucca. "Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs." Epileptic Disorders 16, no. 4 (December 2014): 409–31. http://dx.doi.org/10.1684/epd.2014.0714.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Siegel, Miles G., and Michal Vieth. "Drugs in other drugs: a new look at drugs as fragments." Drug Discovery Today 12, no. 1-2 (January 2007): 71–79. http://dx.doi.org/10.1016/j.drudis.2006.11.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Hu, Xingsheng, Chunhong Hu, Ping Zhong, Yajing Wen, Yong Yang, Juan Chen, and Xiangyu Chen. "Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China." Dose-Response 18, no. 3 (July 1, 2020): 155932582094974. http://dx.doi.org/10.1177/1559325820949740.

Full text

Abstract:

Objective: To compare the efficacy of 3/4-drugs’ group with 1-drug’s or 2-drugs’ groups in coronavirus disease 2019 (COVID-19). Methods: We included 207 patients confirmed with COVID-19. We compared the viral clearance rate and discharge rate at day 7, 14, 21 and 28, and median time of viral clearance and length of hospitalization in patients treated with 3/4, 1 or 2 drugs. Results: The viral clearance rates of the 3/4-drugs group at day 7, 14 and 21 were significantly lower than those in the 1-drug’s or 2-drugs’ groups (P < 0.05). The median viral clearance days in 3/4-drugs group (13.5 days) were longer than 1-drug’s or 2-drugs’ groups (both were 9 days) (P < 0.001). The patients’ discharge rates in the 3/4-drugs group at day 14 and 21 were significantly lower than that in the 1-drug’s or 2 drugs’ group (P < 0.05). The median length of hospitalization in the 3/4-drugs group was 17 days, which was significantly longer than 11 days in the 1-drug group and 13 days in the 2-drug group (P < 0.05). Conclusion: The efficacy of 1 or 2 antiviral drugs was similar in COVID-19, and 3/4-drug regimens were not associated with clinical improvement. Corticosteroid treatment and more serious disease were also risk factors for viral clearance and patients’discharge.

APA, Harvard, Vancouver, ISO, and other styles

45

Zhukova, D. G., E. S. Fedenko, and A. A. Yudin. "Optimal drugs concentrations and doses for allergological diagnostics of perioperative drugs hypersensitivity reactions." Russian Journal of Allergy 12, no. 1 (December 15, 2015): 27–33. http://dx.doi.org/10.36691/rja475.

Full text

Abstract:

Background. The study aimed to develop the optimal concentration and doses of drugs for examination of perioperative drug’s hypersensitivity reactions. Methods. The protocol of allergological examination included clinical, laboratory methods and tests in vivo: skin tests (prick-, intradermal, patch- test) with neuromuscular blockers, opioids, radiocontrast medias, colloids, hypnotics; patch-test with povidon-iodine, chlorhexidine; dosing provocative test (including investigation of blood, nasal secretion eosinophilia, serum tryptase measurements) with antibiotics, nonsteroid anti-inflammatory drugs, local anesthetics. 20 healthy volunteers were included in the study during 2 years (2010-2012) for estimating of the doses and concentrations of testing drugs. Results. Non irritating concentrations for skin tests (prick- and intradermal) with perioperative drugs have been estimated on healthy controls. No one of healthy controls had false positive tests and nonspecific histamine-release effects while testing in vivo. Increased tryptase level 1 h after and the level of blood eosinophilia and eosinophiliaof nasal secretion 6 hours after dosing provocation test with each drug were found to be statistically insignificant. Conclusions. Optimal concentrations and doses of drugs for allergological examination of perioperative drug’s hypersensitivity reactions were estimated.

APA, Harvard, Vancouver, ISO, and other styles

46

Sharma, Neha. "Immunoauppresive Drugs for Renal Transplantation." International Journal of Trend in Scientific Research and Development Volume-3, Issue-2 (February 28, 2019): 561–72. http://dx.doi.org/10.31142/ijtsrd21413.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Oye, Dr Oye, N. D. Vivian, Nathaniel Vivian, and Nathaniel Nathaniel. "DRUGS VERIFICATION AND MANAGEMENT SYSTEM." International Journal of Innovative Research in Engineering & Management 5, no. 1 (January 2018): 35–41. http://dx.doi.org/10.21276/ijirem.2018.5.1.8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Matheson, Ingrid. "Drugs and breast-feeding: When drugs matter." Acta Obstetricia et Gynecologica Scandinavica 73, no. 2 (January 1994): 163–64. http://dx.doi.org/10.3109/00016349409013423.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Inamdar, Nazma, Shima Edalat, VikramB Kotwal, and Sunita Pawar. "Herbal drugs in milieu of modern drugs." International Journal of Green Pharmacy 2, no. 1 (2008): 2. http://dx.doi.org/10.4103/0973-8258.39154.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Mitchell, L. Brent, Judy L. Powell, Anne M. Gillis, Victoria Kehl, and Alfred P. Hallstrom. "Are lipid-lowering drugs also antiarrhythmic drugs?" Journal of the American College of Cardiology 42, no. 1 (July 2003): 81–87. http://dx.doi.org/10.1016/s0735-1097(03)00498-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!